Publish in this journal
Journal Information
Vol. 53. Issue 11.
Pages 654-655 (November 2017)
Vol. 53. Issue 11.
Pages 654-655 (November 2017)
Letter to the Editor
DOI: 10.1016/j.arbr.2017.04.020
Full text access
Core-Needle Biopsy in the Diagnosis of Lung Cancer
Biopsia con aguja gruesa en el diagnóstico de cáncer de pulmón
Visits
864
Jorge Lima Álvarez
Corresponding author
jorgelial@hotmail.com

Corresponding author.
, Alberto Beiztegui Sillero
Unidad de Gestión Clínica de Neumología, Hospital Universitario Virgen de Valme, Sevilla, Spain
This item has received
864
Visits
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

We read with great interest the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer, published as a special issue in May 2016.1

We found it well adapted to the needs of the pulmonologist today.

However, in the subsection on minimally invasive techniques in the section dealing with cytohistological confirmation and staging studies, we were surprised to find that core needle biopsy (CNB) was not included among the techniques described.

This is a very similar procedure to transthoracic fine needle aspiration biopsy (TFNAB). The same guidance techniques, generally computed tomography (CT) and sometimes the ultrasound, are used in both. The main difference between the two procedures is the caliber of the needle, generally 18G, which can yield specimens 1 or 2cm thick, depending on the particular characteristics of the needle and the lesion. The caliber means that the needle track must always be anesthetized. The pulmonologists practicing in our hospital use both techniques. Capalbo et al.2 compared the two procedures in the diagnosis of pulmonary lesions, and reported a greater sensitivity for TFNAB (94.83%) compared to CNB (81.82%).

As confirmed by the literature, this technique has been used for years in the diagnosis of lung cancer, with an acceptable rate of complications.3 The size of the specimen is greater than that obtained by the TFNAB, making it particularly suitable for studying genetic mutations in lung tumors, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), among others. Although some centers are capable of performing these determinations from cytological samples, these laboratory techniques are not as widely implemented as studies performed on the histological sample, and as Schneider et al.4 demonstrated, CNB may be more cost-effective than TFNAB for the study of mutations.

In short, we believe that CNB should be included in paragraph 3.d on minimally invasive techniques of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer, along with bronchoscopy, blind transbronchial aspiration, endobronchial ultrasonography, gastrointestinal endoscopic ultrasonography, electromagnetic navigation bronchoscopy, fine needle aspiration biopsy, thoracentesis, pleural biopsy, and TFNAB, as another diagnostic procedure in non-small cell lung cancer.

References
[1]
F.V. Álvarez, I.M. Trueba, J.B. Sanchis, L.M. López-Rodó, P.M. Rodríguez Suárez, J.S. de Cos Escuín, et al.
Recommendations of the Spanish Society of Pneumology and Thoracic Surgery on the diagnosis and treatment of non-small-cell lung cancer.
Arch Bronconeumol, 52 (2016), pp. S2-S62
[Article in English, Spanish]
[2]
E. Capalbo, M. Peli, M. Lovisatti, M. Cosentino, P. Mariani, E. Berti, et al.
Trans-thoracic biopsy of lung lesions: FNAB or CNB? Our experience and review of the literature.
Radiol Med, 119 (2014), pp. 572-594
[3]
Y. Li, Y. Du, H.F. Yang, J.H. Yu, X.X. Xu.
CT-guided percutaneous core needle biopsy for small (≤20mm) pulmonary lesions.
Clin Radiol, 68 (2013), pp. 43-48
[4]
F. Schneider, M.A. Smith, M.C. Lane, L. Pantanowitz, S. Dacic, N.P. Ohori.
Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas.
Am J Clin Pathol, 143 (2015), pp. 193-200

Please cite this article as: Lima Álvarez J, Beiztegui Sillero A. Biopsia con aguja gruesa en el diagnóstico de cáncer de pulmón. Arch Bronconeumol. 2017;53:654–655.

Copyright © 2017. SEPAR
Idiomas
Archivos de Bronconeumología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.